Search Results - "Gerbens, L."

Patient‐Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement by Spuls, P.I., Gerbens, L.A.A., Simpson, E., Apfelbacher, C.J., Chalmers, J.R., Thomas, K.S., Prinsen, C.A.C., Kobyletzki, L.B., Singh, J.A., Williams, H.C., Schmitt, J.

“…Summary Background The Harmonising Outcome Measures for Eczema (HOME) initiative has defined four core outcome domains for a core outcome set (COS) to be…”
Get full text

European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy by Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H.A., Calzavara Pinton, P., Christen‐Zäch, S., Deleuran, M., Dittmann, M., Dressler, C., Fink‐Wagner, A.H., Fosse, N., Gáspár, K., Gerbens, L., Gieler, U., Girolomoni, G., Gregoriou, S., Mortz, C.G., Nast, A., Nygaard, U., Redding, M., Rehbinder, E.M., Ring, J., Rossi, M., Serra‐Baldrich, E., Simon, D., Szalai, Z.Z., Szepietowski, J.C., Torrelo, A., Werfel, T., Flohr, C.

“…The evidence‐ and consensus‐based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development…”
Get full text

European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populations by Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H.A., Calzavara Pinton, P., Christen‐Zäch, S., Deleuran, M., Dittmann, M., Dressler, C., Fink‐Wagner, A.H., Fosse, N., Gáspár, K., Gerbens, L., Gieler, U., Girolomoni, G., Gregoriou, S., Mortz, C.G., Nast, A., Nygaard, U., Redding, M., Rehbinder, E.M., Ring, J., Rossi, M., Serra‐Baldrich, E., Simon, D., Szalai, Z.Z., Szepietowski, J.C., Torrelo, A., Werfel, T., Flohr, C.

“…The evidence‐ and consensus‐based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development…”
Get full text

Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review by Gerbens, L. A. A., Prinsen, C. A. C., Chalmers, J. R., Drucker, A. M., Kobyletzki, L. B., Limpens, J., Nankervis, H., Svensson, Å., Terwee, C. B., Zhang, J., Apfelbacher, C. J., Spuls, P. I.

“…Background Symptoms have been identified as a core outcome domain for atopic eczema (AE) trials. Various instruments exist to measure symptoms in AE, but they…”
Get full text

Phototherapy for atopic dermatitis: A survey of European practice by Steyn, M., Gerbens, L. A. A., Spuls, P. I., Mashayekhi, S., Deleuran, M., Barbarot, S., Wollenberg, A., Ferguson, J., Ibbotson, S., Flohr, C.

“…Background Phototherapy is used to treat atopic dermatitis (AD). Evidence for its efficacy, impact on quality of life, cost‐effectiveness and short‐ and…”
Get full text

Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data by Wijs, L.E.M., Bosma, A.L., Erler, N.S., Hollestein, L.M., Gerbens, L.A.A., Middelkamp‐Hup, M.A., Kunkeler, A.C.M., Nijsten, T.E.C., Spuls, P.I., Hijnen, D.J.

“…Summary Background Dupilumab is the first biologic registered for the treatment of moderate‐to‐severe atopic dermatitis (AD), and efficacy was shown in phase…”
Get full text

Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting by Thomas, K.S., Apfelbacher, C.A., Chalmers, J.R., Simpson, E., Spuls, P.I., Gerbens, L.A.A., Williams, H.C., Schmitt, J., Gabes, M., Howells, L., Stuart, B.L., Grinich, E., Pawlitschek, T., Burton, T., Howie, L., Gadkari, A., Eckert, L., Ebata, T., Boers, M., Saeki, H., Nakahara, T., Katoh, N.

“…Summary Background The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical…”
Get full text

Implementation of the HOME core outcome set for clinical trials of atopic eczema—barriers and opportunities: the HOME IX meeting report by Jacobson, M. E., Thomas, K. S., Apfelbacher, C. J., Leshem, Y. A., Williams, H. C., Gerbens, L. A. A., Spuls, P. I., Schmitt, J., Howells, L., Katoh, N., Simpson, E. L.

“…The Harmonising Outcome Measures for Eczema (HOME) initiative established a core outcome set (COS) for atopic eczema (AE) clinical trials in 2019. This set…”
Get full text

Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review by Gerbens, L.A.A., Chalmers, J.R., Rogers, N.K., Nankervis, H., Spuls, P.I.

“…Summary ‘Symptoms’ is a core outcome domain for atopic eczema (AE) trials, agreed by consensus as part of the Harmonising Outcome Measures for Eczema (HOME)…”
Get full text

The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate‐to‐severe atopic eczema by Vermeulen, F.M., Gerbens, L.A.A., Schmitt, J., Deleuran, M., Irvine, A.D., Logan, K., Ouwerkerk, W., Vestergaard, C., Flohr, C., Spuls, P.I.

“…Summary Background For many years dermatologists have had access to few therapies for patients with moderate‐to‐severe atopic eczema (AE). New promising…”
Get full text

First update of the living European guideline (EuroGuiDerm) on atopic eczema by Wollenberg, A, Kinberger, M, Arents, B, Aszodi, N, Barbarot, S, Bieber, T, Brough, H A, Pinton, P C, Christen-Zaech, S, Deleuran, M, Dittmann, M, Fosse, N, Gáspár, K, Gerbens, L A A, Gieler, U, Girolomoni, G, Gregoriou, S, Mortz, C G, Nast, A, Nygaard, U, Rehbinder, E M, Ring, J, Rossi, M, Roxburgh, C, Serra-Baldrich, E, Simon, D, Szalai, Z Z, Szepietowski, J C, Torrelo, A, Werfel, T, Flohr, C

Get full text

Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series by Bosma, A. L., Gerbens, L. A. A., Middelkamp‐Hup, M. A., Spuls, P. I.

“…Dupilumab is a relatively new treatment option for patients with moderate to severe atopic dermatitis. There is a lack of knowledge about the effects of…”
Get full text

Methotrexate and azathioprine for severe atopic dermatitis: a 5‐year follow‐up study of a randomized controlled trial by Gerbens, L.A.A., Hamann, S.A.S, Brouwer, M.W.D., Roekevisch, E., Leeflang, M.M.G., Spuls, P.I.

“…Summary Background Systemic treatment is indicated for moderate‐to‐severe atopic dermatitis (AD) refractory to topical treatment. Long‐term evidence, up to 5…”
Get full text

TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries by Vermeulen, F.M., Gerbens, L.A.A., Bosma, A.L., Apfelbacher, C.J., Irvine, A.D., Arents, B.W.M., Barbarot, S., Deleuran, M., Eichenfield, L.F., Manca, A., Schmitt, J., Vestergaard, C., Wall, D., Weidinger, S., Middelkamp‐Hup, M.A., Spuls, P.I., Flohr, C.

“…Summary Background Comparative, real‐life and long‐term evidence on the effectiveness and safety of phototherapy and systemic therapy in moderate‐to‐severe…”
Get full text

Real‐world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry by Musters, A. H., Lookeren, F. L., Gang, L. F., Middelkamp‐Hup, M. A., Bosma, A. L., Jessurun, N. T., Lapeere, H., Nguyen, A. L., Ouwerkerk, W., Schepper, S., Gerbens, L. A. A., Spuls, P. I.

“…Background Evidence on the (long‐term) safety of systemic immunomodulating therapies in atopic dermatitis (AD) generated by real‐world data is sparse…”
Get full text

TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo‐ and systemic therapy registries by Gerbens, L.A.A., Apfelbacher, C.J., Irvine, A.D., Barbarot, S., Booij, R.J., Boyce, A.E., Deleuran, M., Eichenfield, L.F., Hof, M.H., Middelkamp‐Hup, M.A., Roberts, A., Schmitt, J., Vestergaard, C., Wall, D., Weidinger, S., Williamson, P.R., Flohr, C., Spuls, P.I.

“…Summary Background Evidence of immunomodulatory therapies to guide clinical management of atopic eczema (AE) is scarce, despite frequent and often off‐label…”
Get full text

TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema by Bosma, A.L., Spuls, P.I., Garcia‐Doval, I., Naldi, L., Prieto‐Merino, D., Tesch, F., Apfelbacher, C.J., Arents, B.W.M., Barbarot, S., Baselga, E., Deleuran, M., Eichenfield, L.F., Gerbens, L.A.A., Irvine, A.D., Manca, A., Mendes‐Bastos, P., Middelkamp‐Hup, M.A., Roberts, A., Seneschal, J., Svensson, Å., Thyssen, J.P., Torres, T., Vermeulen, F.M., Vestergaard, C., Kobyletzki, L.B., Wall, D., Weidinger, S., Schmitt, J., Flohr, C.

“…Summary Background A long‐term prospective observational safety study is essential to characterize fully the safety profile of systemic immunomodulating…”
Get full text

The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of use by Jacobson, M E, Morimoto, R Y, Leshem, Y A, Howells, L, Williams, H C, Grinich, E, Gerbens, L A A, Spuls, P I, Schmitt, J, Staley, B, Baghoomian, W, Katoh, N, Thomas, K S, Apfelbacher, C J, Simpson, E L

“…The Eczema Area and Severity Index is an investigator-assessed instrument reporting clinical signs of atopic dermatitis. The instrument is extensively…”
Get full text

Do patient characteristics matter when calculating sample size for eczema clinical trials? by Howells, L., Gran, S., Chalmers, J. R., Stuart, B., Santer, M., Bradshaw, L., Gaunt, D. M., Ridd, M. J., Gerbens, L. A. A., Spuls, P. I., Huang, C., Francis, N. A., Thomas, K. S.

“…Background The Patient‐Oriented Eczema Measure (POEM) is the core outcome instrument recommended for measuring patient‐reported atopic eczema symptoms in…”
Get full text

Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) by Chalmers, J.R., Simpson, E., Apfelbacher, C.J., Thomas, K.S., von Kobyletzki, L., Schmitt, J., Singh, J.A., Svensson, Å., Williams, H.C., Abuabara, K., Aoki, V., Ardeleanu, M., Awici-Rasmussen, M., Barbarot, S., Berents, T.L., Block, J., Bragg, A., Burton, T., Bjerring Clemmensen, K.K., Creswell-Melville, A., Dinesen, M., Drucker, A., Eckert, L., Flohr, C., Garg, M., Gerbens, L.A.A., Graff, A.L.B., Hanifin, J., Heinl, D., Humphreys, R., Ishii, H.A., Kataoka, Y., Leshem, Y.A., Marquort, B., Massuel, M.-A., Merhand, S., Mizutani, H., Murota, H., Murrell, D.F., Nakahara, T., Nasr, I., Nograles, K., Ohya, Y., Osterloh, I., Pander, J., Prinsen, C., Purkins, L., Ridd, M., Sach, T., Schuttelaar, M.-L. A., Shindo, S., Smirnova, J., Sulzer, A., Synnøve Gjerde, E., Takaoka, R., Vestby Talmo, H., Tauber, M., Torchet, F., Volke, A., Wahlgren, C.-F., Weidinger, S., Weisshaar, E., Wollenberg, A., Yamaga, K., Zhao, C.Y., Spuls, P.I.

“…Summary This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmö, Sweden on 23–24 April…”
Get full text